Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.
Gastrointestinal Malignancies
DRUG: Lurbinectedin 4 MG Injection [Zepzelca]
Evaluate the antitumor activity, To evaluate the antitumor activity of Lurbinectedin in terms of overall response rate (ORR), according to RECIST v.1.1, in patients with advanced pancreatic cancer with DNA repair mutations., Initiation of study treatment up to 10 cycles (each cycle is 21 days ± 48 hours)
Duration of response (DOR), Duration of response (DOR), defined as the time from the date when the response criteria (PR or CR) are fulfilled to the date of PD, recurrence or death., Initiation of study treatment up to study completion, up to 2 years|Clinical benefit, Clinical benefit, defined as the percentage of patients with ORR or SD ≥4 months, according to RECIST v.1.1., Initiation of study treatment up to study completion, up to 2 years|Measure amount of CA19-9, CEA, or CA125, Measure amount of CA19-9, CEA, or CA125 (whichever is being followed) in blood during treatment., Initiation of study treatment up to 12 cycles (each cycle is 21 days ± 48 hours)|Progression-free survival (PFS), Progression-free survival (PFS), defined as the time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation., Initiation of study treatment up to 12 cycles (each cycle is 21 days ± 48 hours)|Progression-free survival rate at three months (PFS3), Progression-free survival rate at three months (PFS3), defined as the percentage of patients who are alive and progression-free three months after the first infusion., Initiation of study treatment up to three months after the first infusion|Overall survival (OS), Overall survival (OS), defined as the time from the date of first infusion to the date of death (of any cause) or last patient contact., Initiation of study treatment up to 2 years|Overall survival rate at six months (OS6), Overall survival rate at six months (OS6), defined as the percentage of patients who were alive six months after the first infusion, Initiation of study treatment up to six months after the first infusion|Overall survival rate at 12 months (OS12), Overall survival rate at 12 months (OS12), defined as the percentage of patients who were alive 12 months after the first infusion, Initiation of study treatment up to 12 months after the first infusion|Treatment safety, Treatment safety: AEs, serious AEs (SAEs) and laboratory abnormalities graded according to the NCI-CTCAE v.5, Initiation of study treatment up to 2 years
The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.